Disease relevance of Luliconazole

• Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis [1].
• The results suggest that NND-502 might be beneficial in the treatment of Malassezia-associated skin diseases [2].
• In addition to the murine model of systemic aspergillosis, intravenous NND-502 was shown to be highly effective in a rat model of pulmonary aspergillosis compared with intravenous AmB; 90% of animals survived at a dose of 2.5 mg/kg per day of NND-502 while only 30% of animals escaped death when 5 mg/kg per day of AmB was used [3].
• In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses [4].

High impact information on Luliconazole

• In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent [5].
• A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis [6].
• The MIC90 of luliconazole for these two species of dermatophytes was the same, at 0.001 microg/ml, and these values were 4 times, 30 times, and more than 1000 times lower than those of lanoconazole, terbinafine, and bifonazole, respectively [4].
• The luliconazole susceptibility tests were performed with a total of 58 fungal strains of 23 species of fungi grouped into dermatophytes, dematiaceous fungi, hyaline hyphomycetes, yeastlike fungi, and zygomycetes using a broth microdilution method with RPMI 1640 medium [7].
• Information on these six drugs was obtained via an English language search of PubMed through the US National Library of Medicine. The antimycotic agents reviewed include rilopirox, lanoconazole, NND-502, butenafine, eberconazole and voriconazole [8].

Chemical compound and disease context of Luliconazole

• The in vitro antifungal activity of luliconazole, a novel topical imidazole, against pathogenic fungi implicated in dermatomycoses was studied [4].
• The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of tinea pedis (interdigital-type and plantar-type) [6].

Analytical, diagnostic and therapeutic context of Luliconazole

• The minimum inhibitory concentrations (MICs) of luliconazole against T. rubrum and T. mentagrophytes were in the range of 0.00012-0.004 microg/ml and 0.00024-0.002 microg/ml, respectively [4].

References